HomeHealth

Health

MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus

MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus

September 17, 2024

Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease

September 17, 2024

MEDIA ADVISORY – CMA to livestream apology to Indigenous Peoples on Sept. 18

MEDIA ADVISORY – CMA to livestream apology to Indigenous Peoples on Sept. 18

September 16, 2024

Maison Law Accident & Injury Lawyers Donates a New, One-of-a-Kind Outdoor Mobility Training Facility to Kaweah Health Rehabilitation Hospital in Visalia

Maison Law Accident & Injury Lawyers Donates a New, One-of-a-Kind Outdoor Mobility Training Facility to Kaweah Health Rehabilitation Hospital in Visalia

September 16, 2024

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers

September 16, 2024

Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer

Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer

September 16, 2024

Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

September 16, 2024

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

September 15, 2024

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

September 15, 2024

Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

September 15, 2024

« 1 … 28 29 30 31 32 … 127 »